Volume 5, Issue 10: CFTR-Modifying Therapies PODCAST

e-Cystic Fibrosis Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with Cystic Fibrosis. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.

(Volume 5, Issue 10)

Target Audience

Nurses and health care professionals involved in the care of patients with Cystic Fibrosis.

Learning Objectives

After participating in this activity, the participant will demonstrate the ability to:  

  • Explain the relevance of specific mutations in people with CF to new therapies currently available or likely to be approved in the near future.
  • Identify which patients are suitable for disease modifying therapies based on mutation class. 
  • Evaluate the clinical trial data on the use of combination disease modifying therapy in patients with CF and who are homozygous for the F508del mutation. 
Additional information
Contact email: 
Course summary
Available credit: 
  • 0.50 ANCC
  • 0.50 Attendance
Course opens: 
08/20/2015
Course expires: 
08/19/2017
Cost:
$0.00
Stuart Elborn, MD   
Professor, School of Medicine, Dentistry and Biomedical Sciences
Dean, School of Medicine, Dentistry and Biomedical Sciences
Centre for Infection and Immunity
Queen’s University
Belfast, Ireland

Disclosure

Dr. Stuart Elborn has disclosed that he has served as a consultant for Vertex. He has received research support from Vertex, Gilead, and Novartis. In addition, his institution has a consortium with Boehringer.

Unlabeled/Unapproved Uses

Dr. Stuart Elborn has disclosed that he will discuss off label or unapproved uses of lumcaftor, ivacaftor, and ataluren. 

Available Credit

  • 0.50 ANCC
  • 0.50 Attendance

Accreditation Period

Course opens: 
08/20/2015
Course expires: 
08/19/2017

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

Make sure your Adobe flash is updated by clicking HERE